Custom Report

La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

More info

LUND, Sweden I March 9, 2016 I Cantargia AB (“Cantargia”) has received data from the second toxicity study of the company’s CAN04 product candidate. This second study was conducted using a higher dose level and repeated doses. In accordance with the first study, no signs of toxicity were observed.

The new toxicity study investigated repeated treatment with the product candidate CAN04 at doses up to 10 mg/kg. Following the finalization of the study the data has been analysed and the results show that the treatment did not give rise to any negative effects. These results further support that CAN04 will have a good safety profile in patients and strengthen the positive impression obtained from single-dose treatment at a dose level of 5 mg/kg in the first toxicity study that was communicated in November 2015.

“The outcome of the toxicity study is very encouraging, and the results support our positioning of CAN04 as a safe and effective cancer treatment. We are continuing our efforts towards the clinical study phase”, CEO Göran Forsberg says.

SOURCE: Cantargia

Post Views: 72